Drug Profile

Research programme: muscle atrophy antibody oligonucleotide conjugate therapy - Avidity Biosciences

Alternative Names: AOC-Muscle atrophy

Latest Information Update: 06 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Avidity Biosciences
Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Oligonucleotides; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

27 Feb 2026 Avidity Biosciences has been acquired by Novartis
28 Jun 2024 No recent reports of development identified for preclinical development in Muscle-wasting in USA (Parenteral)
19 May 2020 Preclinical trials in Muscular atrophy in USA (Parenteral) (Avidity Biosciences website, May 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com